Potent inhibition of human platelets by cGMP analogs independent of cGMP-dependent protein kinase

Blood

Volumn 103, Issue 7, 2004, Pages 2593-2600

  Gambaryan, Stepan ^a   Geiger, Jörg ^a   Schwarz, Ulrike R ^a   Butt, Elke ^a   Begonia, Antonija ^a   Obergfell, Achim ^a   Walter, Ulrich ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Institut fur Klinische Biochemie und Pathobiochemie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PROSTACYCLIN; THROMBIN; THROMBOXANE; VON WILLEBRAND FACTOR;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 1642411578     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-09-3349     Document Type: Article

References (27)

1. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8:1227-1234.
2. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov. 2003;2:15-28.
3. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-126.
4. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
5. Massberg S, Brand K, Gruner S, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation, J Exp Med. 2002;196:887-896.
6. Burger PC, Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion development. Blood. 2003;101:2661-2666.
7. Huo Y, Schober A, Forlow SB, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med.2003;9:61-67.
8. Lohmann SM, Vaandrager AB, Smolenski A, Walter U, De Jonge HR. Distinct and specific functions of cGMP-dependent protein kinases. Trends Biochem Sci. 1997;22:307-312.
9. Hofmann F, Ammendola A, Schlossmann J. Rising behind NO: cGMP-dependent protein kinases. J Cell Sci. 2000;113(pt 10):1671-1676.
10. Schwarz UR, Walter U, Eigenthaler M. Taming platelets with cyclic nucteotides. Biochem Pharmacol. 2001;62:1153-1161.
11. Tremblay J, Gerzer R, Hamet P. Cyclic GMP in cell function. Adv Second Messenger Phosphoprotein Res. 1988;22:319-383.
12. Münzel T, Feil R, Mülsch A, et al. Physiology and pathophysiology of vascular signaling controled by cGMP-dependent protein kinase. Circulation. 2003;108:2172-2183.
13. Haslam RJ, Dickinson NT, Jang EK. Cyclic nucleotides and phosphodiesterases in platelets. Thromb Haemost. 1999;82:412-423.
14. Eigenthaler M, Ullrich H, Geiger J, et al. Defective nitrovasodilator-stimulated protein phosphorylation and calcium regulation in cGMP-dependent protein kinase-deficient human platelets of chronic myelocytic leukemia. J Biol Chem. 1993;268:13526-13531.
15. Massberg S, Sausbier M, Klatt P, et al. Increased adhesion and aggregation of platelets lacking cyclic guanosine 3',5'-monophosphate kinase 1. J Exp Med. 1999;189:1255-1264.
16. Smolenski A, Bachmann C, Reinhard K, et al. Analysis and regulation of vasodilator-stimulated phosphoprotein serine 239 phosphorylation in vitro and in intact cells using a phosphospecific monoclonal antibody. J Biol Chem. 1998;273:20029-20035.
17. Smolenski A, Poller W, Walter U, Lohmann SM. Regulation of human endothelial cell focal adhesion sites and migration by cGMP-dependent protein kinase 1. J Biol Chem. 2000;275:25723-25732.
18. Li Z, Xi X, Du X. A mitogen-activated protein kinase-dependent signaling pathway in the activation of platelet integrin alpha IIbbeta3. J Biol Chem. 2001;276:42226-42232.
19. Li Z, Xi X, Gu M, et al. A stimulatory role for cGMP-dependent protein kinase in platelet activation. Cell. 2003;112:77-86.
20. Li Z, Ajdic J, Eigenthaler M, Du X. A predominant role for cAMP-dependent protein kinase in the cGMP-induced phosphorylation of vasodilator-stimulated phosphoprotein and platelet inhibition in humans. Blood. 2003;101:4423-4429.
21. Smolenski A, Burkhardt AM, Eigenthaler M, et al. Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO/cGMP effects. Naunyn Schmiedebergs Arch Pharmacol. 1998;358:134-139.
22. Burkhardt M, Glazova M, Gambaryan S, et al. KT5823 inhibits cGMP-dependent protein kinase activity in vitro but not in intact human platelets and rat mesangial cells. J Biol Chem. 2000;275:33536-33541.
23. Baln J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J. 2003;371:199-204.
24. Shimizu-Albergine M, Rybalkin SD, Rybalkina IG, et al. Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs): in vivo phosphorylation of cGMP-specific PDE (PDE5) as an indicator of cGMP-dependent protein kinase (PKG) activation. J Neurosci. 2003;23:6452-6459.
25. Eigenthaler M, Nolte C, Halbrugge M, Walter U. Concentration and regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one of their major substrates in human platelets: estimating the rate of cAMP-regulated and cGMP-regulated protein phosphorylation in intact cells. Eur J Biochem. 1992;205:471-481.
26. Marshall SJ, Senis YA, Auger JM, et al. GPIb-dependent platelet activation is dependent on Src kinases but not MAP kinase or cGMP-dependent kinase. Blood. 2004;103:2601-2609.
27. Aktas B, Utz A, Hoenig-Liedl P, Walter U, Geiger J. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies. Stroke. 2003;34:764-769.